ecancermedicalscience最新文献

{"title":"Gastric cancer in Central America: a scoping review.","authors":"Jade Tso, Mustafa Al-Qaraghli, Susana Galeas, Mustafa Faleh Abidalhassan, Cameron E Gaskill","doi":"10.3332/ecancer.2025.1834","DOIUrl":"10.3332/ecancer.2025.1834","url":null,"abstract":"<p><p>Stomach cancer is the second most common cause of cancer-related death in Central Latin America and the fifth most common cancer by incident in the region. Understanding the epidemiology of stomach cancer is crucial to the appropriate planning, implementation and evaluation of comprehensive cancer control programs. The objective of this scoping review was to quantify the population-based incidence of stomach cancer in Central America from available data, identify reported risk factors, presentation and oncologic stage and explore the frequency of treatment used and survival outcomes for stomach cancer in Central America. Primary reports, cancer registries, hospital registries, endoscopy registries, case studies and case series focusing on the epidemiology of gastric cancer in Belize, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua and Panama, along with its treatment modalities and mortality rates were included. After identifying 616 citations, 20 studies met the inclusion criteria and were selected for data extraction. 12 were from Costa Rica and 5 from Honduras, with few studies from other countries such as Belize, El Salvador and Panama. Crude rates of gastric adenocarcinoma varied widely across different studies, with rates ranging from 0.09/100,000 to 32.04/100,000 in Costa Rica between 1996 and 2015. Overall, there was a general decrease in crude rates over recent study periods. Studies in El Salvador and Panama reported lower crude rates compared to Costa Rica. Non-cardia cancers were more common than cardia cancers. Surgery was the main treatment discussed in the reviewed papers. Mortality data were limited. Our review highlights the need for reliable cancer registries in this region. Often, cancer registries provide the only opportunity for properly assessing the extent and nature of cancer burdens in developing countries. This information is crucial in creating priorities for cancer control public health programs.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1834"},"PeriodicalIF":1.2,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world data on the efficacy and toxicity of induction chemotherapy in locally advanced nasopharyngeal carcinoma in a non-endemic population.","authors":"Cassio Murilo Hidalgo Filho, Gabriel Berlingieri Polho, Otavio Augusto Moreira, Matheus de Oliveira Andrade, Vinicius Cruz Parrela, Yumi Ricucci Shinkado, Amanda Acioli de Almeida Robatto, Felippe Lazar Neto, Ana Julia Freitas, Aurelio Teixeira Souza, Gilberto de Castro Junior, Milena Perez Mak","doi":"10.3332/ecancer.2025.1832","DOIUrl":"10.3332/ecancer.2025.1832","url":null,"abstract":"<p><strong>Background: </strong>Induction chemotherapy (ICT) is critical for managing locally advanced nasopharyngeal carcinoma (LA-NPC), but real-world data on its efficacy and toxicity are limited.</p><p><strong>Methods: </strong>This retrospective study included LA-NPC patients treated with ICT from 2012 to 2022. We evaluated radiological response rates, overall survival (OS), treatment-related toxicities and complete response (CR) rates.</p><p><strong>Results: </strong>Among 217 patients, 119 met the inclusion criteria and were included in the final analysis. CR rates were similar across ICT regimens (docetaxel, cisplatin and 5-fluorouracil 68.0%; cisplatin and gemcitabine 57.1%; cisplatin and 5-fluorouracil 58.0%; others 50%, <i>p</i> = 0.72). Serious adverse events (SAEs) occurred in 22%, with 69.7% experiencing weight loss and 31.9% requiring enteral tube placement. Poor OS was linked to Eastern Cooperative Oncology Group performance status (ECOG-PS) ≥2 hazard ratios (HR 2.8, <i>p</i> = 0.004) and residual disease (RD) (HR 7.4, <i>p</i> = 0.001). Stage IV (Odds Ratio [OR] 3.77, p = 0.005) and ECOG-PS ≥ 2 (OR 4.69, <i>p</i> = 0.006) were associated with RD.</p><p><strong>Conclusion: </strong>ICT regimens had similar CR rates. Poor ECOG-PS and stage IV predicted RD. Managing toxicities is crucial for better outcomes.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1832"},"PeriodicalIF":1.2,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959135/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Germinal pathogenic CHEK2, novel APC and somatic JAK2V617F variants in a young patient with colorectal cancer, atypical leukemia, cerebral tumour and aggressive course.","authors":"Lisa Ximena Rodriguez Rojas, Jorge Andrés Olave Rodriguez, Sebastián Bonilla Navarrete, Laura Valentina Carvajal, Juan José Albán Silva, Liliana Doza Martínez, Jose Antonio Nastasi Catanese","doi":"10.3332/ecancer.2025.1833","DOIUrl":"10.3332/ecancer.2025.1833","url":null,"abstract":"<p><p>Higher CHEK2 and JAK2 expression have been correlated with better survival among patients with rectal adenocarcinoma, lung squamous cell carcinoma, breast cancer, ovarian cancer and several other cancer types. It has been suggested that genome alterations due to lowered or loss of CHEK2 and JAK2 expression may exacerbate cancer progression and predict poor patient survival. In this report, we present the clinical case of a 35-year-old patient exhibiting multiple tumours, an aggressive course, whose genetic analysis revealed a germinal mutation in CHEK2 gen, somatic JAK2V617F and a germinal novel variant in Adenomatous Polyposis Coli (APC) gene of uncertain significance may account for the polyposis and medulloblastoma in the patient, given the variant's genomic location. It is also possible that two germline mutations (CHEK2 and APC) are causing two concurrent conditions in the patient with poorer clinical course.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1833"},"PeriodicalIF":1.2,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges of osteosarcoma care in Africa: a scoping review of the burden, management and outcome.","authors":"Oluwaseun J Olajugba, Emmanuel O Oladeji, Damilola Adesola, Ridwanullah O Abdullateef, Godwin Rockson, Abdul K Bah, Oluwatobi O Olayode","doi":"10.3332/ecancer.2025.1835","DOIUrl":"10.3332/ecancer.2025.1835","url":null,"abstract":"<p><p>Osteosarcoma has the highest incidence among individuals of African descent, with growing evidence suggesting ethnic and racial genetic underpinning. Hence, it presents a grave public health challenge in Africa given the widening inequities in access to cancer care. This scoping review addresses the critical gap in the availability of locally relevant data on the magnitude of the burden and challenges relating to the management and outcome of African centres. This study included 1,374 patients from eighteen studies. 81% presented with locally advanced or metastatic disease. While surgical treatment for osteosarcoma is shifting toward limb salvage on a global scale, amputation remains preponderant in Africa as only 53% underwent limb salvage operations. The pooled 5-year overall survival was 49.1%. Late presentation, workforce and infrastructural shortage, cultural beliefs, patronage of unorthodox medicine practitioners and high healthcare costs were the barriers driving poor outcomes in African centres. Strategies to improve outcomes should focus on addressing these barriers.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1835"},"PeriodicalIF":1.2,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959130/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is the gemcitabin-cisplatin combination the optimal induction chemotherapy for non-Asian patients with nasopharyngeal carcinoma (NPC)? Insights from a cohort in northeastern Morocco.","authors":"Oumaima Talbi, Khadija Hinaje, Samia Mhirech, Kaoutar Maadin, Imad Chakri, Lamiae Amaadour, Karima Oualla, Zineb Benbrahim, Touria Bouhafa, Nawfel Mellas, Samia Arifi","doi":"10.3332/ecancer.2025.1829","DOIUrl":"10.3332/ecancer.2025.1829","url":null,"abstract":"<p><p>According to the latest guidelines for nasopharyngeal carcinoma (NPC), induction chemotherapy (IC) followed by concomitant chemoradiation therapy is recommended as the preferred standard of care for patients with locally advanced NPC (stage III-IVA). However, the optimal regimen for IC in patients with locally advanced NPC remains uncertain.</p><p><strong>Purpose: </strong>We conducted a retrospective study to compare the effectiveness and tolerability of two platinum-based IC regimens; gemcitabine - Cisplatin (GC), and doxorubicin-Cisplatin (DP) in the treatment of newly diagnosed locally advanced NPC. The main objective of this study was to compare efficacy, including objective response rates (ORRs), progression-free survival (PFS), overall survival (OS) and safety.</p><p><strong>Results: </strong>105 patients were satisfied with the eligibility criteria and were, therefore, selected for analysis (62 patients in the DP group and 43 in the GC group), including 65 men and 40 women, with a mean age of 49.5 years (range = 19-79 years) and a Karnofsky score ranging from 87% to 100%. 34% of patients were diagnosed at stage IVA.In the DP group, 3% of patients (2 out of 62) achieved a complete response complete response (CR), 60% achieved a partial response (PR), 25% remained stable S and 19% experienced progression. In the GC group, 2% of patients (1 out of 43) achieved a CR, 39.5% achieved a PR, 39.5% remained stable and 19% experienced progression. A statistically significant difference in PR was observed between the two groups (<i>p</i> = 0.028), and the difference in terms of progression is approaching the limit of significance (<i>p</i> = 0,06) after a median follow-up of 27 months (5.3-82). The 2-year PFS was 70% in the DP group compared to 80% in the GC group; the 2-year OS was 75% in the DP group and 90% in the GC group. No significant survival difference was observed between the two groups.Patients in the DP group exhibited less grade 3-4 thrombocytopenia but more grade 3-4 leukopenia and neutropenia compared to the GC group.</p><p><strong>Conclusion: </strong>In patients with locally advanced NPC, DP-based IC demonstrated superior ORR compared with the GC regimen, with acceptable toxicity. Further studies are required to validate these results.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1829"},"PeriodicalIF":1.2,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multispecialty sessions model for comprehensive care and decision-making in cancer patients.","authors":"Kiara S Berumen, Alberto Sánchez-Navarro, Andrea Velázquez, Manuel Solano, Francisco Anaya, Gustavo Rosales, Alexandra Díaz, Johana Jazer, Kathia Zamudio, Susana Suder, Marisol Quintero, Adriana González-Martínez, Luis A García","doi":"10.3332/ecancer.2025.1830","DOIUrl":"10.3332/ecancer.2025.1830","url":null,"abstract":"<p><p>The management of the oncology patient is complex, due to late diagnosis, treatment and costs, affecting the medical, psychological, nutritional and economic areas. The creation of a multispecialty team, with specialists from health and other fields, is the characteristic of the institute. Since 1920, multidisciplinary has evolved and stood out in developed countries; in Mexico and continues to grow. Although it presents challenges, such as lack of time and coordination, its implementation significantly improves the comprehensive approach to patients.</p><p><strong>Methods: </strong>A retrospective study conducted at the Instituto Oncológico Nacional (ION) in Guadalajara, Mexico, was conducted from April 2019 to December 2023, involving multispecialty sessions via Zoom for oncology patients. Information were collected from medical records with specific inclusion criteria, for the creation of a database in Excel and subsequent analysis with the IBM SPSS Statistics 22 tool.</p><p><strong>Results: </strong>93.09% of the patients were placed in a specialised unit, while 6.91% in 'other tumours'. 37.2% of the sessions were held to establish treatment, 32% for diagnosis and 30.8% for both. The breast tumour unit had the most sessions (15%) and the robotic surgery unit had the least sessions (0.8%). 74.9% of the cases required one session and 25.1% required more sessions. An average saving of 5 consultations were generated; 68.8% of the sessions met their objectives and were followed up.</p><p><strong>Conclusion: </strong>Multispecialty virtual sessions in ION generate significant benefits: they reduce waiting times, save resources, improve access to specialised units and a comprehensive approach. Success is due to team coordination, communication between specialists and patients and implementation of decision making. It is recommended to promote this approach to optimise clinical outcomes and quality of life, overcoming logistical barriers and evaluating its long-term impact.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1830"},"PeriodicalIF":1.2,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959129/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrent dedifferentiated liposarcoma with histological grade progression: a case report.","authors":"Samuel Santiago Parra Giraldo, Rut Amparo Vergara López, Haydee De La Hoz-Herazo, Enrique Carlos Ruiz Pla, Brayan Bayona-Pacheco, Juan Jose Espitia De La Hoz","doi":"10.3332/ecancer.2025.1831","DOIUrl":"10.3332/ecancer.2025.1831","url":null,"abstract":"<p><strong>Introduction: </strong>Dedifferentiated liposarcoma (DDLPS) is a rare mesenchymal neoplasm that accounts for approximately 20% of soft tissue sarcomas in the human body. This case report emphasises a high-grade DDLPS with a retroperitoneal location and its unexpected recurrence in a 72-year-old male patient more than 10 years after the primary tumour. This case is particularly significant because of the anomalous presentation of the tumour recurrence time that is complemented by the unusual histologic features of the initial neoplasm, which raises new questions about the biological behaviour of the disease, the clinical course and the management of this pathology.</p><p><strong>Expected results: </strong>The report seeks to highlight the important and unusual aspects of the pathology that can contribute to a better understanding of its evolution, allowing informed clinical decisions to improve the patient's quality of life and prognosis.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1831"},"PeriodicalIF":1.2,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pioneering psycho-oncology: A collaborative journey for medical and psychology students at <i>e</i>cancer-Tata Medical Center Kolkata Psycho-oncology Congress 2024.","authors":"Soumitra Shankar Datta, Heena Sheth, Sharmili Ghosh, Srijan Das, Jigeesha Ghosh, Dishari Choudhury, Arnab Mukherjee, Soumita Ghose, Romy Biswas, Maria Castrillo Gil, Carlos Andres Gamboa Alfaro, Mary Guevara, Danny Burke, Sujit Sarkhel, Jai Ranjan Ram","doi":"10.3332/ecancer.2025.1828","DOIUrl":"10.3332/ecancer.2025.1828","url":null,"abstract":"<p><p>Psycho-oncology is an upcoming specialisation that encompasses the psychological and social aspects of cancer care. In an integrated psycho-oncology service, consultant psychiatrists and clinical psychologists come together with other professionals to treat comorbid psychiatric disorders of cancer patients and their caregivers. Psycho-oncologists also contribute to improving clinician-patient communication, address staff burnout and conduct translational research. The <i>e</i>cancer-Tata Medical Center Kolkata Psycho-oncology Congress, 2024 was an initiative to encourage multi-disciplinary learning in undergraduate and postgraduate medical and psychology students and early career professionals. Written feedback from 106 participants who comprised 71% (71%, 106/149) of the pre-registered delegates, showed that the overwhelming majority found the overall experience as 'excellent' (75/106, 70.75%) or 'good' (27/106, 25%). The qualitative free-text feedback expressed the desire for longer psycho-oncology conferences 'spread over two days', eagerness to learn about qualitative and quantitative 'research methods' and specific therapeutic techniques used to treat common psychiatric comorbidities in cancer patients. A video providing an overview of the event is available here: https://ecancer.org/en/video/12232-reflections-after-the-ecancer-tata-medical-center-kolkata-psycho-oncology-congress-2024. This event generated a set of educational videos on psycho-oncology that are available online here: https://ecancer.org/en/conference/1551-ecancer-tmc-kolkata-psycho-oncology-congress.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1828"},"PeriodicalIF":1.2,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959143/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Duration of intervals in the care-seeking pathway of lung cancer in Nepal.","authors":"Shama Pandey, Bishnu Dutta Paudel, Bibek Acharya, Sandhya Chapagain Acharya, Ambuj Karn, Saugat Poudyal, Manish Poudel, Pradeep Thapa, Jasmine Gurung, Ramila Shilpakar","doi":"10.3332/ecancer.2025.1825","DOIUrl":"10.3332/ecancer.2025.1825","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with lung cancer in Nepal often present at an advanced stage. The purpose of this study was to determine the access, diagnostic and treatment intervals in patients with lung cancer and to identify factors that may be causing the delays leading to advanced presentation.</p><p><strong>Methods: </strong>This was a descriptive, cross-sectional study conducted in the Department of Clinical Oncology, Bir Hospital from July 2023 to April 2024 after obtaining ethical approval from the Institutional Review Board. Patients with newly diagnosed lung cancer were interviewed and data was collected. Data were presented in the forms of percentages and mean/median. Univariate and multivariate logistic regression analysis was done to assess the association between various factors and different delays.</p><p><strong>Results: </strong>Of the 100 patients included, 56% were men and the mean age was 64.5 ± 10.8 years. 64% of the patients had stage IV disease. The median access, diagnostic and treatment interval were 44.5 days, 45.5 days and 26 days, respectively. Access, diagnostic and treatment delays were seen in 72%, 63% and 42% of the patients, respectively. Receiving empirical anti-tubercular treatment and visiting informal healthcare providers as their first healthcare contact was associated with diagnostic delay whereas smoking was associated with treatment delay.</p><p><strong>Conclusion: </strong>There is a significant delay in the care-seeking pathway of lung cancer in Nepal. Implementing corrective measures to address these could help improve the outcomes for these patients.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1825"},"PeriodicalIF":1.2,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The burden of pancreatic cancer in Latin America and the Caribbean: trends in incidence, mortality and DALYs from 1990 to 2019.","authors":"Diego Rodrigues Mendonça E Silva, Max Moura de Oliveira, Gisele Aparecida Fernandes, Maria Paula Curado","doi":"10.3332/ecancer.2025.1827","DOIUrl":"10.3332/ecancer.2025.1827","url":null,"abstract":"<p><p>This study analyzed the burden of pancreatic cancer by investigating its incidence, mortality and disability-adjusted life years (DALYs), as well as the proportion of pancreatic cancer deaths attributable to behavioural and metabolic risk factors in Latin America and the Caribbean (LAC) countries.</p><p><strong>Methods: </strong>This study focuses on pancreatic cancer using the Global Burden of Disease 2019 study database. Results were described for 23 LAC countries for 1990-2019, evaluating their age-standardised incidence rates, mortality rates, DALYs, average annual percent change and the fraction of deaths attributable to behavioural and metabolic risk factors.</p><p><strong>Results: </strong>We observed that in LAC, pancreatic cancer incidence rates ranged from 1.2 in Haiti to 15.8/100,000 in Uruguay among men. The highest increase in incidence rate was observed in Trinidad and Tobago: 7.7% per year. The mortality rate was higher in Uruguay and lower in Haiti, for both sexes. The highest rise in the numbers of DALYs in 2019 was observed in Brazil and Mexico. The proportion of pancreatic cancer deaths attributable to smoking was reduced between 1990 and 2019 for both sexes in LAC countries; however, it increased for metabolic risk factors.</p><p><strong>Conclusion: </strong>The increasing trend in pancreatic cancer observed in LAC may be associated with a rise in risk factors such as high fasting plasma glucose and high body mass index in both sexes. This trend will likely have a substantial impact on the healthcare system in the coming decades.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1827"},"PeriodicalIF":1.2,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}